16:51 , Apr 22, 2019 |  BioCentury  |  Finance

Poseida's sea change

Rather than execute the IPO it proposed in January, Poseida has instead raised a $142 million series C round that includes a $75 million contribution from Novartis. CEO Eric Ostertag told BioCentury that Poseida has...
23:59 , Dec 11, 2018 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Breast cancer Mouse studies suggest a vaccine based on a tetanus toxoid-MUC1 conjugate could help treat MUC1-expressing breast cancer. The conjugate consists of a 22-mer human MUC1 peptide conjugated to tetanus toxoid carrier protein,...
18:32 , Nov 30, 2018 |  BC Week In Review  |  Company News

GEn1E gains rights to MUC1 IP

GEn1E Lifesciences Inc. (Palo Alto, Calif.) gained an exclusive option to license patent rights to mucin 1 (MUC1; CD227) decoy peptides from the University of Maryland Baltimore (Baltimore, Md.) to treat and prevent bacterial infections....
23:49 , Oct 22, 2018 |  BC Extra  |  Clinical News

Roche reports responses for IL-2 variant at ESMO

A targeted IL-2 variant from Roche (SIX:ROG; OTCQX:RHHBY) showed monotherapy activity in patients with metastatic solid tumors in a Phase I trial. Data presented Sunday at the European Society for Medical Oncology in Munich from...
17:34 , Aug 3, 2018 |  BC Week In Review  |  Company News

Daiichi in ADC deal for Glycotope's anti-mucin antibody

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX). Glycotope will receive an undisclosed upfront payment...
18:16 , Jul 30, 2018 |  BC Extra  |  Company News

Daiichi in ADC deal for Glycotope's anti-mucin antibody

Glycotope GmbH (Berlin, Germany) granted Daiichi Sankyo Co. Ltd. (Tokyo:4568) exclusive, worldwide rights to develop and commercialize an antibody-drug conjugate to treat cancer using Glycotope's gatipotuzumab (formerly PankoMab-GEX). Glycotope will receive an undisclosed upfront payment...
23:25 , Mar 2, 2018 |  BioCentury  |  Product Development

Clever pegylation pay off

Nektar Therapeutics’ clever pegylation strategy allowed it to finesse the PK and dial down the toxicity of IL-2, turning a validated but problematic immuno-oncology mechanism into a viable candidate. The approach snagged a record-breaking deal...
22:04 , Dec 1, 2017 |  BC Week In Review  |  Company News

Daiichi, Glycotope partner for cancer ADC

Daiichi Sankyo Co. Ltd. (Tokyo:4568) and Glycotope GmbH (Berlin, Germany) partnered to develop an antibody-drug conjugate (ADC) to treat cancer by combining Daiichi's ADC technology with Glycotope's PankoMab-GEX, a humanized IgG1 antibody targeting mucin 1...
17:50 , Nov 2, 2017 |  BC Innovations  |  Product R&D

Sweet specificity

Siamab Therapeutics Inc. is gearing up to compete in the small but active space of companies targeting sugar groups that are up-regulated in cancer. So far, its technology has produced a lead therapeutic, a deal...
21:00 , Jun 22, 2017 |  BC Innovations  |  Targets & Mechanisms

Exosomes deliver

Codiak BioSciences Inc. founder Raghu Kalluri has published the first animal data demonstrating exosomes can be used as drug delivery vehicles to treat cancer -- not just diagnose it. The findings also mark the unveiling...